Everest Medicines
云顶新耀
Executive Summary
Everest Medicines is a Hong Kong-listed biotech with clear BIOSECURE status, making it an attractive Chinese partner for US pharma. Under CEO Kerry Blanchard since 2023, the company has pivoted from oncology to autoimmune/renal diseases with nefecon for IgA nephropathy as a key asset in-licensed from Calliditas. Shanghai-based with strong deal-making credentials and no BIOSECURE designation concerns.
Structure: Everest Medicines trades on Hong Kong Stock Exchange (1952.HK) with headquarters in Shanghai, suggesting a typical Hong Kong holding company structure for Chinese operations. No VIE structure complications apparent from available data, which should simplify due diligence and contract negotiations for US partners.
Key People
| Name | Title | Education | Flags |
|---|---|---|---|
Kerry Blanchard 陈博 | CEO | MD, PhD; Former CMO at Vertex Pharmaceuticals |
Ownership & Shareholder Structure
Everest Medicines → AbbVie
Everest licensed multiple AbbVie assets for Greater China development.
BIOSECURE Risk
Company has clear BIOSECURE status with no BCC designation, reducing regulatory risk for US partnerships
Key Exposures:
- •Potential future policy changes
- •Shanghai operational base subject to US-China tensions
Mitigation: Hong Kong listing and clear regulatory status provide structural protection from BIOSECURE Act restrictions
BD Intelligence
Therapeutic Areas:
Recent Deals: Strategic in-licensing of nefecon from Calliditas demonstrates active BD capability and therapeutic area focus
Approach: Approach through CEO Kerry Blanchard given recent leadership change and strategic pivot - company likely seeking partnerships to strengthen autoimmune/renal portfolio
Red Flags
- ⚠Limited subsidiary visibility may indicate incomplete corporate structure disclosure
- ⚠Recent CEO change suggests potential organizational transition risks
- ⚠Pivot from oncology to autoimmune may indicate pipeline challenges in original focus area
Quick Facts
- Key People
- 1
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 1
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.